edoc

Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis : a randomised extension of the TRANSFORMS study

Khatri, Bhupendra and Barkhof, Frederik and Comi, Giancarlo and Hartung, Hans-Peter and Kappos, Ludwig and Montalban, Xavier and Pelletier, Jean and Stites, Tracy and Wu, Stacy and Holdbrook, Fred and Zhang-Auberson, Lixin and Francis, Gordon and Cohen, Jeffrey A. and Transforms Study Group, . (2011) Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis : a randomised extension of the TRANSFORMS study. The Lancet neurology, Vol. 10, H. 6. pp. 520-529.

Full text not available from this repository.

Official URL: http://edoc.unibas.ch/dok/A6006991

Downloads: Statistics Overview

Abstract

In a 12-month phase 3 study in patients with relapsing-remitting multiple sclerosis (RRMS), TRANSFORMS, fingolimod showed greater efficacy on relapse rates and MRI outcomes compared with interferon beta-1a. We had two aims in our extension: to compare year 2 with year 1 in the switched patients to assess the effect of a change from interferon beta-1a to fingolimod, and to compare over 24 months the treatment groups as originally randomised to assess the effect of delaying the start of treatment with fingolimod.
Faculties and Departments:03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Neurologie > Neuroimmunologie (Kappos)
UniBasel Contributors:Kappos, Ludwig
Item Type:Article, refereed
Article Subtype:Research Article
Bibsysno:Link to catalogue
Publisher:Elsevier
ISSN:1474-4465
Note:Publication type according to Uni Basel Research Database: Journal article
Identification Number:
Last Modified:06 Dec 2013 09:36
Deposited On:06 Dec 2013 09:36

Repository Staff Only: item control page